News & Press Releases
News & Press Releases
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
IAVA and Myriad Genetics Host Live Event to Raise Awareness about Genetic Testing and Mental Health
IAVA Partners with Myriad Genetics
Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial
2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment
Six in 10 of the women surveyed with depression or anxiety diagnosis say they have been ignored or dismissed by family, friends, and/or partners about their mental health concerns
SALT LAKE CITY, April 26, 2022 – Two out of three women diagnosed with depression or anxiety say they have reached or are approaching their breaking point regarding their mental health, according to the GeneSight® Mental Health Monitor, a new nationwide survey from Myriad Genetics, Inc. (NASDAQ: MYGN).
Myriad Genetics Announces Upgrades to the GeneSight® Test
New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test
New Year’s Resolutions: Americans Say Body & Mind Equally Important in Theory but Not in Practice, According to GeneSight® Mental Health Monitor Nationwide Survey
The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults
Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek treatment according to the GeneSight® Mental Health Monitor nationwide survey
Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey
SALT LAKE CITY, September 8, 2021 – Depression medication trial and error is far too common – and may result in additional mental health challenges.
New research reveals most Americans can’t identify the symptoms of depression
GeneSight® Mental Health Monitor finds large gap between what Americans think and what they actually know about recognizing depression. SALT LAKE CITY, July 28, 2021 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a recent nationwide poll, the GeneSight® Mental Health Monitor.